Skip to main content

Table 2 Patients’ baseline characteristics

From: Pooled analysis of combination antiemetic therapy for chemotherapy-induced nausea and vomiting in patients with colorectal cancer treated with oxaliplatin-based chemotherapy of moderate emetic risk

Characteristics

Study A (N = 160)

Study B (N = 157)

SENRI trial (N = 344)

Overall (N = 661)

 

n (%)

n (%)

n (%)

n (%)

Age

  <  65 years

89 (55.6)

92 (58.6)

160 (46.5)

341 (51.6)

  ≥ 65 years

71 (44.4)

65 (41.4)

184 (53.5)

320 (48.4)

Sex

 Male

92 (57.5)

88 (56.1)

211 (61.3)

391 (59.2)

 Female

68 (42.5)

69 (43.9)

133 (38.7)

270 (40.8)

Motion sickness

 No

143 (89.4)

135 (86.0)

282 (82.0)

560 (84.7)

 Yes

17 (10.6)

22 (14.0)

56 (16.3)

95 (14.4)

 Unknown

0 (0.0)

0 (0.0)

6 (1.7)

6 (0.9)

Drinking habit

 No

126 (78.8)

78 (49.7)

245 (71.2)

449 (67.9)

 Yes

34 (21.3)

79 (50.3)

93 (27.0)

206 (31.2)

 Unknown

0 (0.0)

0 (0.0)

6 (1.7)

6 (0.9)

Regimen

 FOLFOX

97 (60.6)

79 (50.3)

83 (24.1)

259 (39.2)

 XELOX

63 (39.4)

78 (49.7)

261 (75.9)

402 (60.8)

Antiemetics

 2

114 (71.3)

157 (100.0)

170 (49.4)

441 (66.7)

 3

46 (28.8)

0 (0.0)

174 (50.6)

220 (33.3)